LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Edwards Lifesciences Corp

Gesloten

SectorGezondheidszorg

78.27 0.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

78.13

Max

78.36

Belangrijke statistieken

By Trading Economics

Inkomsten

-27M

332M

Verkoop

120M

1.5B

K/W

Sectorgemiddelde

32.703

34.427

EPS

0.64

Winstmarge

21.636

Werknemers

15,800

EBITDA

-34M

400M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+13.72% upside

Dividenden

By Dow Jones

Volgende Winsten

23 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

978M

46B

Vorige openingsprijs

78.17

Vorige sluitingsprijs

78.27

Nieuwssentiment

By Acuity

23%

77%

45 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Edwards Lifesciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2025, 18:44 UTC

Acquisities, Fusies, Overnames

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

25 okt 2024, 09:10 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

25 okt 2024, 08:35 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

3 sep 2024, 20:38 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3 sep 2024, 20:37 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3 sep 2024, 20:36 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

Peer Vergelijking

Prijswijziging

Edwards Lifesciences Corp Prognose

Koersdoel

By TipRanks

13.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 89 USD  13.72%

Hoogste 101 USD

Laagste 80 USD

Gebaseerd op 26 Wall Street-analisten die 12-maands prijsdoelen bieden voor Edwards Lifesciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

26 ratings

16

Buy

10

Hold

0

Sell

Technische score

By Trading Central

74.52 / 75.54Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

45 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.